Literature DB >> 10954058

Recent advances in the treatment of bipolar mania, depression, mixed states, and rapid cycling.

J C Soares1.   

Abstract

New pharmacological agents for the treatment of bipolar disorder are under investigation. Some of the new potential treatments attempt to target specific clinical conditions that constitute particular challenges in the management of bipolar individuals. Typical cases of mania traditionally respond well to lithium, but atypical cases, in particular patients with mixed episodes, tend to respond poorly. The pharmacological treatment of bipolar depression is complicated by the phenomenon of rapid cycling, which may make the clinical management of these patients considerably difficult. New therapeutic agents, including new anticonvulsants, atypical antipsychotics, and calcium channel blockers are currently being examined, and bring the promise of substantial advances in the pharmacological management of bipolar patients. Recent developments in this area are reviewed, with a focus on alternatives for the treatment of refractory mania, bipolar depression, mixed states, and rapid cycling patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10954058     DOI: 10.1097/00004850-200015040-00001

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  4 in total

Review 1.  Emerging options in the treatment of bipolar disorders.

Authors:  M Berk; J Segal; L Janet; M Vorster
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Atypical antipsychotics and mood stabilization in bipolar disorder.

Authors:  Paolo Brambilla; Francesco Barale; Jair C Soares
Journal:  Psychopharmacology (Berl)       Date:  2003-02-27       Impact factor: 4.530

3.  Report of three cases that received maintenance treatment with risperidone as a mood stabilizer.

Authors:  Konstantinos N Fountoulakis; Ioannis Nimatoudis; Apostolos Iacovides; George Kaprinis
Journal:  Ann Gen Hosp Psychiatry       Date:  2004-05-26

Review 4.  Cyclooxygenase Inhibition Safety and Efficacy in Inflammation-Based Psychiatric Disorders.

Authors:  Maria Grazia Perrone; Antonella Centonze; Morena Miciaccia; Savina Ferorelli; Antonio Scilimati
Journal:  Molecules       Date:  2020-11-18       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.